Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Latin America Health Times.
Press releases published on May 22, 2025
Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences
GlobeNewswire
·
May 22, 2025
Partner presentations reinforce ability of proprietary Azymetric™ platform to develop clinically validated therapeutic antibodies Long-term outcomes and survival data for Ziihera® (zanidatamab-hrii), which was developed using Azymetric™, to be presented at …
Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting
GlobeNewswire
·
May 22, 2025
BOSTON, May 22, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the publication of an …
Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq
GlobeNewswire
·
May 22, 2025
Cincinnati, OH, May 22, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (the “Company”) announced that it received a Staff delisting letter from The Nasdaq Capital Market (“Nasdaq”) on May 20, 2025 indicating that the Company’s failure to file its …
Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors
GlobeNewswire
·
May 22, 2025
- Renowned neuroscience drug developer joins to support strategic development of long-acting CNS therapeutics – HUNTSVILLE, AL, May 22, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology …
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting
GlobeNewswire
·
May 22, 2025
May 22, 2025 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of …
Bio-Path Holdings to Host Corporate Update Conference Call on May 29, 2025
GlobeNewswire
·
May 22, 2025
HOUSTON, May 22, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, …
All Heart Homecare Wins Best of Brooklyn 2025 for Best Home Health Aides
GlobeNewswire
·
May 22, 2025
BROOKLYN, N.Y., May 22, 2025 (GLOBE NEWSWIRE) -- All Heart Homecare Agency is proud to announce that it has been named the winner of the Best of Brooklyn 2025 Award for Best Home Health Aides. This marks the agency’s fourth win overall and its third …
GENFIT Reports First Quarter 2025 Financial Information
GlobeNewswire
·
May 22, 2025
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 22, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver …
GENFIT : Information financière du premier trimestre 2025
GlobeNewswire
·
May 22, 2025
Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 22 mai 2025 – GENFIT (Nasdaq et Euronext : GNFT), société biopharmaceutique de stade clinique avancé engagée dans l’amélioration de la vie des patients atteints de maladies rares du …
Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors
GlobeNewswire
·
May 22, 2025
Dr. Read brings >30 years of leadership and scientific expertise in the biopharmaceutical industry Previously served as CEO and Founder of Mariana Oncology until its acquisition by Novartis in 2024 and CSO of Ra Pharma until its acquisition by UCB in 2020 …
WORK Medical Technology Group LTD Announces Closing of Registered Offering
GlobeNewswire
·
May 22, 2025
Hangzhou, China, May 22, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and …
Senti Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
GlobeNewswire
·
May 22, 2025
SOUTH SAN FRANCISCO, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene …
Inotiv, Inc. to Present at Jefferies Global Healthcare Conference 2025
GlobeNewswire
·
May 22, 2025
WEST LAFAYETTE, Ind., May 22, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models …
TELA Bio to Participate in the 2025 Jefferies Global Healthcare Conference
GlobeNewswire
·
May 22, 2025
MALVERN, Pa., May 22, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in the 2025 …
Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
GlobeNewswire
·
May 22, 2025
SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced that it has commenced an underwritten public offering of shares of its …
Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
GlobeNewswire
·
May 22, 2025
Immix Biopharma today reported ASCO abstract results from its U.S. multi-center NEXICART-2 Phase 1/2 clinical trial of NXC-201 demonstrating strong efficacy and favorable safety. – NXC-201 demonstrated a complete response (CR) rate of 71% (5/7 patients) – …
Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants
GlobeNewswire
·
May 22, 2025
ISELIN, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has commenced an …
Gyre Therapeutics’ Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in China
GlobeNewswire
·
May 22, 2025
Achieved statistically significant ≥1-stage fibrosis regression at Week 52 vs. placebo (52.85% vs. 29.84%, P=0.0002). Demonstrated favorable safety and tolerability profile: 4.88% serious adverse events vs. 6.45% for placebo; zero discontinuations due to …
PESG Research Report: A Review of Silexion Therapeutics' Innovative KRAS-Driven Cancer Treatment
GlobeNewswire
·
May 22, 2025
New York, May 22, 2025 (GLOBE NEWSWIRE) -- PESG Research today announced the release of a report examining Silexion Therapeutics, an innovative biotechnology company developing unique RNA interference (RNAi) therapies targeting KRAS-driven cancers. The …
Houston Emerges as Global Center for Brain Health Innovation
GlobeNewswire
·
May 22, 2025
HOUSTON, May 22, 2025 (GLOBE NEWSWIRE) -- Protecting and enriching human brain health and performance may be one of the most important economic strategies that businesses and governments pursue as they seek to strengthen workforces, mitigate the surging …